Health Condition 1: M249- Joint derangement, unspecified
Conditions
Interventions
Intervention1: Injection PRP in periarthritis of shoulder: After completely explaining the procedure and written informed consent, all the patients will be divided into study and control groups using
The Study group P will receive autologous PRP injection into the glenohumeral joint.
Total volume of injection drugs: 4ml(1.5ml of triamcinolone acetonide(80mg) + 2.5ml of normal saline)
The number
The study group P will receive PRP injection into the glenohumeral joint. Total volume of injection drugs: 4ml. The number of injections : only once during the study period Injection site : glenohumer
The control group C will receive corticosteroid(triamcinolone acetonide) injection into the glenohumeral joint.
Total volume of injection drugs: 4ml(1.5ml of triamcinolone acetonide(80mg) + 2.5ml of
Sponsors
Department of Anaesthesiology and Critical Care JNMCHAMU Aligarh
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >18 years 2. ASA Grade I and II patients 3. Patients of persistent shoulder pain diagnosed clinically and radiologically 4. More than 1/3rd restriction of shoulder flexion, abduction and external rotation 5. Willingness to participate in the study and forgo any other concomitant treatment modality
Exclusion criteria
Exclusion criteria: 1. Unwillingness to participate in the study 2. Intrinsic glenohumeral pathology 3. History of shoulder trauma or surgery 4. History of injection in the involved shoulder during preceding 6 months 5. Patients with haematological disorders or on antiplatelet or anticoagulant therapy, or hypersensitivity to local anaesthetics, or receiving anticoagulants, aspirin, aspirin containing NSAIDS. 6. Pregnant and breastfeeding females 7. Uncontrolled psychiatric disorder or major depression or other severe medical illness 8. Local infection or ongoing septicaemia 9. Patients with autoimmune disease, malignancy, uncontrolled diabetes mellitus, hyperlipidemia and patients with BMI >30
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the degree and duration of pain relief in patients of periarthritis of shoulder using Numerical Rating Scale (NRS)Timepoint: Baseline, 1st week, 3rd week and 6th week | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate the improvement in shoulder function of patient using Shoulder pain and Disability Index (SPADI) 2. Requirement of rescue analgesics on weekly basis 3. Complications such as pain, bleeding, infection or any other complication occurring during and after injection shall be notedTimepoint: Improvement in shoulder function was assessed in the form of SPADI at 1st, 3rd and 6th week taking the shoulder function at the day of intervention as baseline The analgesics taken by the patient were recorded on weekly basis Any complication occurring was taken into account at 1st, 3rd and 6th week | — |
Countries
India
Contacts
Public ContactIqra Mehak
JNMCH, AMU
Outcome results
None listed